- $47.90m
- -$88.25m
- $0.80m
Ikena Oncology Inc reports results for the quarter ended in March - Earnings Summary
Ikena Oncology Inc expected to post a loss of 41 cents a share - Earnings Preview
Ikena Oncology Inc reports results for the quarter ended in December - Earnings Summary
Ikena Oncology Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Ikena Oncology Outlines Key Priorities And Provides Corporate Updates
U.S. STOCKS ON THE MOVE-Instacart, Nvidia, Novavax
U.S. STOCKS ON THE MOVE-Emeren Group, Tesla, Parker-Hannifin
Ikena Oncology down on missing Q3 revenue estimates
Brief: Ikena Oncology Shares Initial Positive Dose Escalation Data From IK-930 Phase I Trial And Reports Third Quarter 2023 Results
Ikena Oncology Inc expected to post a loss of 43 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Coeur Mining, FedEx, Uber Technologies
Brief: Ikena Oncology Inc Files For Shelf Of Up To 5.95 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Caci International, Cyberark Software, Ralph Lauren
Ikena Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ikena Oncology Q2 EPS USD -0.44
Ikena Oncology Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Ikena Oncology Acquires Pionyr Immunotherapeutics
Brief: Ikena Oncology Inc Says On June 30, Got Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Ikena Oncology Reports First Quarter 2023 Financial Results And Highlights Advancements Across Targeted Oncology Pipeline